Answers are grounded in this paper and cite their sources.
Findings show fezolinetant improves work productivity and lowers costs in women with vasomotor symptoms, suggesting a viable treatment option.
Fezolinetant demonstrated improvements in work productivity and reduced estimated indirect costs versus placebo for women with moderate to severe VMS, including HT-unsuitable women who often face limited treatment options, maintained through 52 weeks.
No takes yet. Share an insight, caveat, or question.
Morga et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: